These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 33920140)

  • 1. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
    Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
    Bahar E; Kim JY; Kim HS; Yoon H
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARL6IP5 reduces cisplatin-resistance by suppressing DNA repair and promoting apoptosis pathways in ovarian carcinoma.
    Kim JY; Bahar E; Lee JY; Chang S; Kim SH; Park EY; Do SI; Yoon H; Kim HS
    Cell Death Dis; 2022 Mar; 13(3):239. PubMed ID: 35293383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
    Ali R; Alabdullah M; Alblihy A; Miligy I; Mesquita KA; Chan SY; Moseley P; Rakha EA; Madhusudan S
    Cancer Lett; 2020 Jan; 469():124-133. PubMed ID: 31669203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
    Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
    Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
    Perez JM; Twigg CAI; Guan W; Thomas SN
    J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance to endoplasmic reticulum stress mediates cisplatin resistance in human ovarian cancer cells by maintaining endoplasmic reticulum and mitochondrial homeostasis.
    Xu Y; Wang C; Su J; Xie Q; Ma L; Zeng L; Yu Y; Liu S; Li S; Li Z; Sun L
    Oncol Rep; 2015 Dec; 34(6):3051-60. PubMed ID: 26398138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIM47 inhibits cisplatin chemosensitivity and endoplasmic reticulum stress-induced apoptosis of ovarian cancer cells.
    Zhao J; Zhang J; Tong X; Zhao L; Cao R
    Mol Cell Probes; 2024 Oct; 77():101978. PubMed ID: 39096978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
    Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
    Baloch T; López-Ozuna VM; Wang Q; Matanis E; Kessous R; Kogan L; Yasmeen A; Gotlieb WH
    BMC Cancer; 2019 Jan; 19(1):44. PubMed ID: 30630446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
    Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
    Xu L; Zhang B; Li W
    Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
    Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
    Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming multidrug resistance by activating unfolded protein response of the endoplasmic reticulum in cisplatin-resistant A2780/CisR ovarian cancer cells.
    Jung E; Koh D; Lim Y; Shin SY; Lee YH
    BMB Rep; 2020 Feb; 53(2):88-93. PubMed ID: 31401981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2
    Biegała Ł; Gajek A; Szymczak-Pajor I; Marczak A; Śliwińska A; Rogalska A
    Sci Rep; 2023 Dec; 13(1):22659. PubMed ID: 38114660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.